Pelareorep
drugOn this page
Also known as PO BB0209PO-BB-0209PO-BB0209ReolysinReovirus 3 (strain dearing)Reovirus type 3 (strain dearing)
Summary
Pelareorep (CHEMBL3545069) is a phase-3 clinical-stage unknown; indicated across 9 conditions including squamous cell carcinoma and squamous cell lung carcinoma.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Unknown
- Indications: 9 conditions
- Clinical trials: 19
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL3545069 |
| Name | Pelareorep |
| Type | Unknown |
| Max phase | 3 |
Also known as: Pelareorep, PO BB0209, PO-BB-0209, PO-BB0209, Reolysin, Reovirus 3 (strain dearing), Reovirus type 3 (strain dearing), PELAREOREP
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
9 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| squamous cell carcinoma | 3 | MONDO:0005096 | EFO:0000707 |
| squamous cell lung carcinoma | 3 | MONDO:0005097 | EFO:0000708 |
| cutaneous melanoma | 2 | MONDO:0005012 | EFO:0000389 |
| metastatic melanoma | 2 | MONDO:0005191 | EFO:0002617 |
| breast neoplasm | 2 | MONDO:0021100 | MONDO:0007254 |
| triple-negative breast carcinoma | 2 | MONDO:0005494 | EFO:0005537 |
| breast carcinoma | 2 | MONDO:0004989 | EFO:0000305 |
| melanoma | 2 | MONDO:0005105 | EFO:0000756 |
| plasma cell myeloma | 1 | MONDO:0009693 | EFO:0001378 |
Clinical trials
Total trials: 19.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 10 |
| PHASE1 | 4 |
| PHASE1/PHASE2 | 3 |
| PHASE3 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01166542 | PHASE3 | COMPLETED | Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers |
| NCT04215146 | PHASE2 | ACTIVE_NOT_RECRUITING | A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study |
| NCT04445844 | PHASE2 | ACTIVE_NOT_RECRUITING | INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study |
| NCT05514990 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial |
| NCT07280377 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab |
| NCT07446322 | PHASE2 | RECRUITING | FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer |
| NCT00984464 | PHASE2 | COMPLETED | Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma |
| NCT00998192 | PHASE2 | COMPLETED | A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung |
| NCT00998322 | PHASE2 | COMPLETED | A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma |
| NCT01199263 | PHASE2 | COMPLETED | Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer |
| NCT01622543 | PHASE2 | COMPLETED | Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer |
| NCT01656538 | PHASE2 | COMPLETED | A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer |
| NCT01708993 | PHASE2 | COMPLETED | Reolysin in Previously Treated Advanced/Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy |
| NCT03282188 | PHASE1/PHASE2 | WITHDRAWN | REO13 Melanoma With of Without GM-CSF |
| NCT02101944 | PHASE1 | COMPLETED | Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma |
| NCT03015922 | PHASE1 | UNKNOWN | Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma |
| NCT03605719 | PHASE1 | COMPLETED | Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma |
| NCT05519059 | PHASE1 | COMPLETED | Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer |
| NCT04102618 | EARLY_PHASE1 | TERMINATED | A Window-of-opportunity Study of Pelareorep in Early Breast Cancer |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).